Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT-PCR.

Acute respiratory illness Disease diagnosis Polymerase chain reaction Respiratory syncytial virus

Journal

Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 18 01 2023
accepted: 06 04 2023
medline: 6 5 2023
pubmed: 6 5 2023
entrez: 6 5 2023
Statut: ppublish

Résumé

Nearly all existing respiratory syncytial virus (RSV) incidence estimates are based on real-time polymerase chain reaction (RT-PCR) testing of nasal or nasopharyngeal (NP) swabs. Adding testing of additional specimen types to NP swab RT-PCR increases RSV detection. However, prior studies only made pairwise comparisons and the synergistic effect of adding multiple specimen types has not been quantified. We compared RSV diagnosis by NP swab RT-PCR alone versus NP swab plus saliva, sputum, and serology. This was a prospective cohort study over two study periods (27 December 2021 to 1 April 2022 and 22 August 2022 to 11 November 2022) of patients aged ≥ 40 years hospitalized for acute respiratory illness (ARI) in Louisville, KY. NP swab, saliva, and sputum specimens were collected at enrollment and PCR tested (Luminex ARIES platform). Serology specimens were obtained at acute and convalescent timepoints (enrollment and 30-60-day visit). RSV detection rate was calculated for NP swab alone and for NP swab plus all other specimen type/test. Among 1766 patients enrolled, 100% had NP swab, 99% saliva, 34% sputum, and 21% paired serology specimens. RSV was diagnosed in 56 (3.2%) patients by NP swab alone, and in 109 (6.2%) patients by NP swab plus additional specimens, corresponding to a 1.95 times higher rate [95% confidence interval (CI) 1.62, 2.34]. Limiting the comparison to the 150 subjects with all four specimen types available (i.e., NP swab, saliva, sputum, and serology), there was a 2.60-fold increase (95% CI 1.31, 5.17) compared to NP swab alone (3.3% versus 8.7%). Sensitivities by specimen type were: NP swab 51%, saliva 70%, sputum 72%, and serology 79%. Diagnosis of RSV in adults was several-fold greater when additional specimen types were added to NP swab, even with a relatively low percentage of subjects with sputum and serology results available. Hospitalized RSV ARI burden estimates in adults based solely on NP swab RT-PCR should be adjusted for underestimation.

Identifiants

pubmed: 37148463
doi: 10.1007/s40121-023-00805-1
pii: 10.1007/s40121-023-00805-1
pmc: PMC10163290
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1593-1603

Informations de copyright

© 2023. Pfizer Inc.

Références

Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71(14):1574–83.
doi: 10.1016/j.jacc.2018.02.013 pubmed: 29622165
Falsey AR, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59.
doi: 10.1056/NEJMoa043951 pubmed: 15858184
Chatzis O, Darbre S, Pasquier J, et al. Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study. BMC Infect Dis. 2018;18(1):1–9.
doi: 10.1186/s12879-018-3002-3
Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197–203.
doi: 10.1093/cid/ciy991 pubmed: 30452608
Branche AR, Saiman L, Walsh EE et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017–2020. Clin Infect Dis. 2020;
Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261–9.
doi: 10.1007/s40266-015-0258-9 pubmed: 25851217
Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis. 2010;50(5):747–51.
pubmed: 20121411
Havers F. Epidemiology and Burden of Respiratory Syncytial Virus in Older Adults in the US. Accessed September 3, 2022. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-22-23/04-RSV-Havers-508.pdf
McLaughlin JM, Khan F, Begier E, et al. Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis. Open Forum Infect Dis. 2022 Jun 17;9(7):ofac300.
Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222(Suppl 7):S577–83.
doi: 10.1093/infdis/jiz059 pubmed: 30880339
Onwuchekwa C, Moreo LM, Menon S et al. Under-ascertainment of Respiratory Syncytial Virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. Poster Presentation. International RSV Symposium, September 2022, Belfast, UK [The Journal of Infectious Diseases. 2023; in Press.]
Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE, Falsey AR. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis. 2013;207:1424–32.
doi: 10.1093/infdis/jit038 pubmed: 23382572 pmcid: 3610422
Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020;383(13):1283–6. https://doi.org/10.1056/NEJMc2016359 .
doi: 10.1056/NEJMc2016359 pubmed: 32857487
Luminex Corporation. ARIES system operation manual, revision E. May 2022.
Cambridge Research Biochemicals. Chambridge Research Biochemicals—Discovery. Accessed September 3, 2022. https://crbdiscovery.com .
Southern Biotech. Antibodies For Research. Accessed September 3, 2022. https://www.southernbiotech.com .
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021; https://www.R-project.org/ .
Kim L, Rha B, Abramson JS, et al. Identifying gaps in respiratory syncytial virus disease epidemiology in the United States prior to the introduction of vaccines. Clin Infect Dis. 2017;65(6):1020–5.
doi: 10.1093/cid/cix432 pubmed: 28903503 pmcid: 5850021
Falsey AR, Formica MA, Walsh EE. Yield of sputum for viral detection by reverse transcriptase PCR in adults hospitalized with respiratory illness. J Clin Microbiol. 2012 Jan;50(1):21–4. doi: https://doi.org/10.1128/JCM.05841-11 Epub 2011 Nov 16. PMID: 22090400; PMCID: PMC3256730.
Jeong JH, Kim KH, Jeong SH, Park JW, Lee SM, Seo YH. Comparison of sputum and nasopharyngeal swabs for detection of respiratory viruses. J Med Virol. 2014 Dec;86(12):2122–7. https://doi.org/10.1002/jmv.23937 Epub 2014 May 6. PMID: 24797344; PMCID: PMC7166652.
Song M, Wilde AM, Moore SE, et al. False-negative SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) is an important consideration for patient management and infection prevention: a case report from the louisville COVID-19 epidemiology study. The Univ Louisville J Respiratory Infect. 2020;4(1):43.
Lee F Eun-Hyung, Halliley JL, Sanz I, Falsey AR, Walsh EE. Circulating Antibody Secreting Cells during Acute Respiratory Syncytial Virus infection in Adults. J Infect Dis 2010;202(11):1659–66.
Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, Nair H. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther. 2023;20:1–13. https://doi.org/10.1007/s40121-023-00792-3
doi: 10.1007/s40121-023-00792-3

Auteurs

Julio Ramirez (J)

Norton Infectious Diseases Institute, Norton Healthcare, 601 S Floyd St, Louisville, KY, 40202, USA. Julio.Ramirez@nortonhealthcare.org.

Ruth Carrico (R)

Norton Infectious Diseases Institute, Norton Healthcare, 601 S Floyd St, Louisville, KY, 40202, USA.

Ashley Wilde (A)

Norton Infectious Diseases Institute, Norton Healthcare, 601 S Floyd St, Louisville, KY, 40202, USA.

Alan Junkins (A)

Norton Infectious Diseases Institute, Norton Healthcare, 601 S Floyd St, Louisville, KY, 40202, USA.

Stephen Furmanek (S)

Norton Infectious Diseases Institute, Norton Healthcare, 601 S Floyd St, Louisville, KY, 40202, USA.

Thomas Chandler (T)

Norton Infectious Diseases Institute, Norton Healthcare, 601 S Floyd St, Louisville, KY, 40202, USA.

Paul Schulz (P)

Norton Infectious Diseases Institute, Norton Healthcare, 601 S Floyd St, Louisville, KY, 40202, USA.

Robin Hubler (R)

Pfizer Inc, Collegeville, PA, USA.

Paula Peyrani (P)

Pfizer Inc, Collegeville, PA, USA.

Qing Liu (Q)

Pfizer Inc, Collegeville, PA, USA.

Sonali Trivedi (S)

Pfizer Inc, Collegeville, PA, USA.

Sonal Uppal (S)

Pfizer Inc, Collegeville, PA, USA.

Warren V Kalina (WV)

Pfizer Inc, Collegeville, PA, USA.

Ann R Falsey (AR)

Department of Medicine, Infectious Diseases Division, University of Rochester Medical Center, Rochester, NY, 14642, USA.

Edward E Walsh (EE)

Department of Medicine, Infectious Diseases Division, University of Rochester Medical Center, Rochester, NY, 14642, USA.

Kari Yacisin (K)

Pfizer Inc, Collegeville, PA, USA.

Luis Jodar (L)

Pfizer Inc, Collegeville, PA, USA.

Bradford D Gessner (BD)

Pfizer Inc, Collegeville, PA, USA.

Elizabeth Begier (E)

Pfizer Inc, Collegeville, PA, USA.

Classifications MeSH